adverum (nasdaq: advm) is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. we are advancing the development of a robust pipeline of gene therapies that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (a1at) deficiency and hereditary angioedema (hae) as well as wet age-related macular degeneration (wamd). leveraging our next-generation adeno-associated virus (aav)-based directed evolution platform, we generate gene therapies designed to provide durable efficacy by inducing sustained expression of a therapeutic protein.
Company profile
Ticker
ADVM
Exchange
Website
CEO
Leone Patterson
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Avalanche Biotechnologies, Inc.
SEC CIK
Corporate docs
Subsidiaries
Avalanche Australia PTY LTD • Annapurna Therapeutics, LTD • Adverum NC, LLC ...
ADVM stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
1 Apr 24
EFFECT
Notice of effectiveness
27 Mar 24
S-3
Shelf registration
21 Mar 24
424B3
Prospectus supplement
20 Mar 24
8-K
Material Modifications to Rights of Security Holders
20 Mar 24
S-8
Registration of securities for employees
18 Mar 24
10-K
2023 FY
Annual report
18 Mar 24
8-K
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
18 Mar 24
S-3
Shelf registration
4 Mar 24
D
$127.80 mm in equity / options, sold $127.80 mm, 20 investors
21 Feb 24
Latest ownership filings
4
Setareh Seyedkazemi
12 Mar 24
4
Peter Soparkar
12 Mar 24
4
Laurent Fischer
12 Mar 24
SC 13G
Logos Global Management LP
22 Feb 24
SC 13G
TCG Crossover GP II, LLC
15 Feb 24
SC 13G/A
Venrock Healthcare Capital Partners III, L.P.
14 Feb 24
4
Setareh Seyedkazemi
14 Feb 24
4
Laurent Fischer
14 Feb 24
SC 13G
Vivo Opportunity Fund Holdings, L.P.
14 Feb 24
4
Linda M Rubinstein
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 108.02 mm | 108.02 mm | 108.02 mm | 108.02 mm | 108.02 mm | 108.02 mm |
Cash burn (monthly) | 1.94 mm | (no burn) | 11.51 mm | 10.98 mm | 7.97 mm | 7.34 mm |
Cash used (since last report) | 12.90 mm | n/a | 76.52 mm | 73.01 mm | 52.99 mm | 48.78 mm |
Cash remaining | 95.12 mm | n/a | 31.49 mm | 35.01 mm | 55.02 mm | 59.23 mm |
Runway (months of cash) | 49.0 | n/a | 2.7 | 3.2 | 6.9 | 8.1 |
Institutional ownership, Q3 2023
39.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 65 |
Opened positions | 12 |
Closed positions | 7 |
Increased positions | 15 |
Reduced positions | 20 |
13F shares | Current |
---|---|
Total value | 97.89 bn |
Total shares | 82.91 mm |
Total puts | 200.00 |
Total calls | 90.20 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Commodore Capital | 10.00 mm | $15.00 bn |
MS Morgan Stanley | 6.98 mm | $10.46 bn |
FMR | 6.69 mm | $10.04 bn |
VR Adviser | 6.57 mm | $9.86 bn |
Venrock Healthcare Capital Partners III | 5.90 mm | $11.86 mm |
Versant Venture Management | 5.07 mm | $7.60 bn |
Versant Ventures IV | 5.00 mm | $70.11 mm |
BML Investment Partners | 4.95 mm | $5.69 mm |
BAC Bank Of America | 4.77 mm | $7.15 bn |
GS Goldman Sachs | 4.56 mm | $6.83 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
7 Feb 24 | Lupher, Jr. Mark L. | Common Stock | Buy | Acquire P | No | No | 1.35 | 130,000 | 175.50 k | 130,000 |
7 Feb 24 | Scopa James Paul | Common Stock | Buy | Acquire P | No | No | 1.35 | 100,000 | 135.00 k | 100,000 |
3 Nov 23 | C. David Nicholson, | Stock Option Common Stock | Grant | Acquire A | No | No | 0.9312 | 80,000 | 74.50 k | 80,000 |
3 Oct 23 | Setareh Seyedkazemi | Stock Option Common Stock | Grant | Acquire A | No | No | 1.29 | 85,000 | 109.65 k | 85,000 |
News
Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
20 Mar 24
RBC Capital Maintains Sector Perform on Adverum Biotechnologies, Lowers Price Target to $2
19 Mar 24
Adverum Biotechnologies Announces 1-For-10 Reverse Stock Split To Be Effective March 21, 202
18 Mar 24
Adverum Biotechnologies Q4 EPS $(0.23) Beats $(0.34) Estimate
18 Mar 24
Why Is Blindness Focused-Adverum Biotechnologies Stock Trading Lower Today?
8 Feb 24
Press releases
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
18 Mar 24
Thinking about buying stock in Adverum Biotechnologies, Roma Green Finance, Wah Fu Education, ESSA Pharma, or Science 37?
16 Feb 24
Thinking about buying stock in Gorilla Technology, Li Auto, Osisko Mining, Adverum Biotechnologies, or Kingsoft Cloud?
6 Feb 24
Adverum Biotechnologies Announces $127.5 Million Private Placement Financing
5 Feb 24
Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024
1 Feb 24